Eledon
2 known investors
Eledon develops tegoprubart, an anti-CD40L antibody in clinical development for preventing rejection in organ transplant recipients. The company focuses on improving long-term graft survival and quality of life for transplant recipients across kidney, liver, and xenotransplantation.
Founders & leadership
SP
Steven PerrinPresident and Chief Scientific Officer
Investors · 2
Frequently asked questions
- What does Eledon do?
- Eledon develops tegoprubart, an anti-CD40L antibody in clinical development for preventing rejection in organ transplant recipients. The company focuses on improving long-term graft survival and quality of life for transplant recipients across kidney, liver, and xenotransplantation.
- Who are Eledon's investors?
- Eledon's investors include JDRF T1D Fund, Newpath Partners.